Category - Developments

Developments

Lineage reports additional cases of retinal tissue restoration in dry AMD with OpRegen

Lineage Cell Therapeutics (NASDAQ, TASE:LCTX) reported that restoration of retinal tissue was observed in two additional patients enrolled in the company’s Phase 1/2a study of its lead product candidate, OpRegen. ...

June 1, 2021

Developments

Ripple Therapeutics polymer-free drug delivery published in Nature Communications

An article describing Ripple Therapeutics’ Epidel technology platform entitled, “Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery,” was recently published in the peer-reviewed...

June 1, 2021

Developments

Seelos receives European orphan drug designation for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency Committee for Orphan Medicinal Products. Under orphan...

May 27, 2021

Developments

KA Imaging in U.S. distribution pact with Alpha Imaging

KA Imaging signed a U.S. distribution agreement with Ohio-based Alpha Imaging for its Reveal 35C portable dual-energy X-ray detector. Alpha Imaging is one of the largest distributors of medical imaging equipment in the...

May 26, 2021

Developments

111 Inc. posts 64.7% increase in Q1 net revenue

111 Inc. (NASDAQ:YI), a leading digital healthcare platform in China, posted net revenue of RMB2.6 billion ($396-million U.S.) for the first quarter of 2021, an increase of 64.7%, compared with the same quarter in 2020...

May 19, 2021

Developments

KA Imaging installs 2 mobile X-ray units at University Health Network

Closely-held KA Imaging installed two new mobile X-ray units in the University Health Network of Toronto to enhance current clinical studies and support patient care, with one unit is being used at the Princess Margaret...

May 18, 2021

Developments

Seelos posts positive topline data for acute suicidal ideation and behavior in MDD

Seelos Therapeutics (NASDAQ:SEEL) reported positive data from Part 1, the open-label cohort, of its potentially registrational proof-of-concept study of SLS-002, demonstrating a significant treatment effect and a well...

May 17, 2021

Developments

Arctic Vision in exclusive licensing pact with ActualEyes

Arctic Vision of Shanghai and Japanese-based ActualEyes announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product candidate, AE-101, for the treatment of...

May 14, 2021

Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

May 13, 2021

Developments

IntelGenx expands psychedelics accord with atai

IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a second feasibility agreement with atai Life Sciences AG for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being...

May 12, 2021

Category - Developments

Subscribe